Contemporary Pediatrics week in review: School avoidance, updates in AD treatment, and more
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Contemporary Pediatrics week in review: School avoidance, updates in AD treatment, and more | Image Credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, September 18 to Friday, September 22, 2023) and click each link to read and watch anything you may have missed.
1.) Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
Arcutis submits roflumilast 0.15% sNDAfor AD in children 6 years and up | Image Credit: © lial88 - © lial88 - stock.adobe.com.
Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Click here for the full article.
2.) School avoidance trends and the negative effects associated with excessive missed days
School avoidance trends and the negative effects associated with excessive missed days | Image Credit: Provided by James Wallace, MD
This Contemporary Pediatrics® interview features James Wallace, MD, associate professor, Department of Psychiatry and Pediatrics, University of Rochester Medical Center, Child and Adolescent Psychiatry Faculty Trainer, The REACH Institute. Wallace explains how excessive missed school days can have a negative impact on children, and how these trends have increased since the start of the COVID-19 pandemic.
Click here for the full article.
3.) FDA issues CRL for neffy nasal spray to treat allergic reactions, requests more research
FDA rejects approval of Neffy nasal spray for allergic reactions, requests more research | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com
The FDA issued the Complete Response Letter (CRL) based on the request for a completed pharmacokinetic/pharmacodynamic study to assess how repeat doses of the epinephrine nasal spray compare to repeat doses of an epinephrine injection product. ARS Pharma is set to file a Formal Dispute Resolution Request to appeal the CRL.
Click here for the full article.
4.) Poll: Majority of parents concerned about bad air quality, impact on child's health
Poll: Majority of parents concerned about bad air quality, impact on child's health | Image Credit: © ttlsc - © ttlsc - stock.adobe.com.
According to a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, the recent wildfires and extreme weather events that are creating poor or unhealthy air quality are also causing concern for parents in regard to their children's health.
Click here for the full article.
5.) The problem with patient portals (and how to resolve them)
The problem with patient portals (and how to resolve them) | Image Credit: © woravut - © woravut- stock.adobe.com.
How pediatricians can best manage electronic health records without compromising patient care.
Omalizumab outperforms oral immunotherapy in treating multi-food allergy
March 27th 2025A new clinical trial has found that omalizumab (Xolair; Genetech, Novartis) is more effective than oral immunotherapy (OIT) in treating multi-food allergy in individuals with severe allergic reactions to small amounts of common food allergens.
